The Global Health Body Issues Concern Over Critical Lack of Obesity Injections
Under a tenth of people eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it issues its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with thorough and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant hurdles to widespread availability to the injections that can assist patients in reducing considerable body mass, says the agency.
GLP-1 Therapy Scarcity
Even under the present best projected outlook, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.
The guideline encourages governments and firms to expand access, via approaches including licensing agreements.
Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in multiple countries in 2026.
How Weight-Loss Injections Operate
The injections imitate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so users consume fewer calories.
People commonly see weight reduction within a few weeks of commencing the once-weekly jabs.
Research points to users may see weight return within a year of discontinuing the medication, as their usual appetite resume.
To be above a healthy weight elevates your chance for developing medical conditions, such as diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts people in all nations and was associated with millions of fatalities worldwide in 2024, according to the health agency.
